A. Sarusi-portuguez, M. Schwartz, R. Siersbaek, R. Nielsen, M. Sung et al., Hierarchical role for transcription factors and 2007 chromatin structure in genome organization along adipogenesis. The FEBS, Mandrup, vol.284, pp.3230-3244, 2006.

S. Mandrup, Extensive chromatin remodelling and establishment of 2011 transcription factor 'hotspots' during early adipogenesis, The EMBO journal, vol.2012, pp.1459-1472, 2011.

V. Chandra, P. Huang, Y. Hamuro, S. Raghuram, Y. Wang et al., Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex 2015 on DNA, Nature, pp.350-356, 2008.

T. Roszer, M. P. Menendez-gutierrez, M. Cedenilla, and M. Ricote, Retinoid X 2017 receptors in macrophage biology, Trends Endocrinol Metab, vol.24, pp.460-468, 2013.

T. Ide, H. Shimano, T. Yoshikawa, N. Yahagi, M. Amemiya-kudo et al., , 2019.

M. Nakakuki, S. Yatoh, Y. Iizuka, S. Tomita, K. Ohashi et al., , p.2020

T. Gotoda, J. Osuga, S. Ishibashi, and N. Yamada, Cross-talk between peroxisome 2021 proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in 2022 nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid 2023 degradation gene promoters through inhibition of PPAR signaling, Endocrinol, vol.17, pp.1255-1267, 2003.

T. Yoshikawa, T. Ide, H. Shimano, N. Yahagi, M. Amemiya-kudo et al., , p.2026

S. Yatoh, T. Kitamine, H. Okazaki, Y. Tamura, M. Sekiya et al., Cross-talk between 2028 peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor 2029 (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress 2030 sterol regulatory element binding protein-1c promoter through inhibition of 2031 LXR signaling, Mol Endocrinol, vol.17, pp.1240-1254, 2003.

K. Hashimoto, R. N. Cohen, M. Yamada, K. R. Markan, T. Monden et al., Cross-talk between thyroid hormone receptor and liver X 2034 receptor regulatory pathways is revealed in a thyroid hormone resistance 2035 mouse model, J Biol Chem, vol.281, pp.295-302, 2006.

S. Oka, P. Zhai, T. Yamamoto, Y. Ikeda, J. Byun et al.,

, Peroxisome Proliferator Activated Receptor-alpha Association With Silent 2038 Information Regulator 1 Suppresses Cardiac Fatty Acid Metabolism in the 2039 Failing Heart, Circulation Heart failure, vol.8, pp.1123-1132, 2015.

S. Oka, R. Alcendor, P. Zhai, J. Y. Park, D. Shao et al., , 2041.

J. Sadoshima, PPARalpha-Sirt1 complex mediates cardiac hypertrophy and 2042 failure through suppression of the ERR transcriptional pathway, Cell 2043 metabolism, vol.14, pp.598-611, 2011.

S. Oka, P. Zhai, R. Alcendor, J. Y. Park, B. Tian et al., Vanden Heuvel 2051 JP. The ribosomal protein rpL11 associates with and inhibits the 2052 transcriptional activity of peroxisome proliferator-activated receptor-alpha, Toxicological sciences : an official journal of the Society of Toxicology, vol.11, pp.535-546, 2006.

P. J. Brown, D. A. Winegar, K. D. Plunket, L. B. Moore, M. C. Lewis et al., , p.2500

S. S. Sundseth, C. S. Koble, Z. Wu, J. M. Chapman, J. M. Lehmann et al., , p.2501

T. M. Willson, Journal of medicinal peroxisome-proliferator-activated receptors alpha and delta in fibrate and 2799 fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding 2800 protein in the liver and the small intestine, The Biochemical journal, vol.2801, pp.481-488, 2001.

S. S. Lee, T. Pineau, J. Drago, E. J. Lee, J. W. Owens et al.,

P. M. Salguero, H. Westphal, and F. J. Gonzalez, Targeted disruption of the alpha 2804 isoform of the peroxisome proliferator-activated receptor gene in mice results 2805 in abolishment of the pleiotropic effects of peroxisome proliferators, Molecular and cellular biology, vol.15, pp.3012-3022, 1995.

M. L. Hughes, B. Liu, M. L. Halls, K. M. Wagstaff, R. Patil et al., , p.2808

N. W. Bunnett, M. J. Scanlon, and C. J. Porter, Fatty Acid-binding Proteins 1 and 2 2809 Differentially Modulate the Activation of Peroxisome Proliferator-activated 2810 Receptor alpha in a Ligand-selective Manner, J Biol Chem, vol.290, pp.13895-2811, 2015.

M. B. Sandberg, M. Bloksgaard, D. Duran-sandoval, and C. Duval,

S. Mandrup, The gene encoding acyl-CoA-binding protein is subject to 2814 metabolic regulation by both sterol regulatory element-binding protein and 2815 peroxisome proliferator-activated receptor alpha in hepatocytes, J Biol Chem, vol.2816, pp.5258-5266, 2005.

T. Helledie, L. Grontved, S. S. Jensen, P. Kiilerich, L. Rietveld et al., , p.2818

M. S. Boysen, J. Nohr, L. K. Larsen, J. Fleckner, H. G. Stunnenberg et al., , p.2819

S. Mandrup, The gene encoding the Acyl-CoA-binding protein is activated by 2820 peroxisome proliferator-activated receptor gamma through an intronic 2821 response element functionally conserved between humans and rodents, J Biol, vol.277, pp.26821-26830, 2002.

J. F. Louet, F. Chatelain, J. F. Decaux, E. A. Park, C. Kohl et al., , p.2824

J. P. Pegorier, Long-chain fatty acids regulate liver carnitine 2825 palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-2826 proliferator-activated receptor alpha (PPARalpha)-independent pathway, The 2827 Biochemical journal, vol.354, pp.189-197, 2001.

M. J. Barrero, N. Camarero, P. F. Marrero, and D. Haro, Control of human carnitine 2829 palmitoyltransferase II gene transcription by peroxisome proliferator-activated 2830 receptor through a partially conserved peroxisome proliferator-responsive 2831 element, The Biochemical journal, vol.369, pp.721-729, 2003.

M. Fischer, M. You, M. Matsumoto, and D. W. Crabb, Peroxisome proliferator-2833 activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha 2834 dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice

, J Biol Chem, vol.278, pp.27997-28004, 2003.

T. Gulick, S. Cresci, T. Caira, D. D. Moore, and D. P. Kelly, The peroxisome 2837 proliferator-activated receptor regulates mitochondrial fatty acid oxidative 2838 enzyme gene expression, Proceedings of the National Academy of Sciences of 2839 the United States of America, vol.91, pp.11012-11016, 1994.
DOI : 10.1073/pnas.91.23.11012
URL : http://www.pnas.org/content/91/23/11012.full.pdf

Q. Zhao, R. Yang, J. Wang, D. D. Hu, and F. Li, PPARalpha activation protects against 2841 cholestatic liver injury, Scientific reports, vol.7, p.9967, 2017.
DOI : 10.1038/s41598-017-10524-6
URL : https://www.nature.com/articles/s41598-017-10524-6.pdf

T. Hashimoto, T. Fujita, N. Usuda, W. Cook, C. Qi et al., , p.2843

A. V. Yeldandi, M. S. Rao, and J. K. Reddy, Peroxisomal and mitochondrial fatty acid 2844 beta-oxidation in mice nullizygous for both peroxisome proliferator-activated 2845 receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation 2846 with fatty liver phenotype, J Biol Chem, vol.274, pp.19228-19236, 1999.

, The Biochemical journal, vol.351, pp.747-753, 2000.

M. Marrapodi and J. Y. Chiang, Peroxisome proliferator-activated receptor alpha 2949 (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene 2950 (CYP7A1) transcription, Journal of lipid research, vol.41, pp.514-520, 2000.

P. Tontonoz, E. Hu, J. Devine, E. G. Beale, and B. M. Spiegelman, PPAR gamma 2 2952 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene, Molecular and cellular biology, vol.15, pp.351-357, 1995.

M. C. Sugden, K. Bulmer, G. F. Gibbons, B. L. Knight, and M. J. Holness, Peroxisome-2955 proliferator-activated receptor-alpha (PPARalpha) deficiency leads to 2956 dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and 2957 insulin, The Biochemical journal, vol.364, pp.361-368, 2002.

K. Motojima and K. Seto, Fibrates and statins rapidly and synergistically induce 2959 pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice

, Biological & pharmaceutical bulletin, vol.26, pp.954-958, 2003.

S. Kersten, S. Mandard, N. S. Tan, P. Escher, D. Metzger et al., Characterization of the fasting-induced adipose 2963 factor FIAF, a novel peroxisome proliferator-activated receptor target gene, J 2964 Biol Chem, vol.275, pp.28488-28493, 2000.

L. Berthou, N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx et al., , 2966.

J. C. Fruchart, E. Rubin, P. Denefle, B. Staels, and D. Branellec, Opposite regulation of 2967 human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein 2968 A-I transgenic mice, J Clin Invest, vol.97, pp.2408-2416, 1996.

J. P. Desager, Y. Horsmans, C. Vandenplas, and C. Harvengt, Pharmacodynamic 2970 activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic 2971 parameters measured in normolipidaemic subjects receiving ciprofibrate (100 2972 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days, Atherosclerosis, vol.124, pp.65-73, 1996.

J. M. Peters, N. Hennuyer, B. Staels, J. C. Fruchart, C. Fievet et al., Auwerx 2975 J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated 2976 receptor alpha-deficient mice, J Biol Chem, vol.272, pp.27307-27312, 1997.

B. Staels, A. Van-tol, T. Andreu, and J. Auwerx, Fibrates influence the expression of 2978 genes involved in lipoprotein metabolism in a tissue-selective manner in the 2979 rat, Arteriosclerosis and thrombosis : a journal of vascular biology, vol.2980, pp.286-294, 1992.

S. Haubenwallner, A. D. Essenburg, B. C. Barnett, M. E. Pape, and R. B. Demattos, , p.2982

B. R. Krause, L. L. Minton, B. J. Auerbach, R. S. Newton, and T. Leff,

, Hypolipidemic activity of select fibrates correlates to changes in hepatic 2984 apolipoprotein C-III expression: a potential physiologic basis for their mode of 2985 action, Journal of lipid research, vol.36, pp.2541-2551, 1995.

J. M. Brandt, F. Djouadi, D. Kelly, M. E. Young, S. Patil et al., Fatty acids activate transcription of the 2987 muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the 2988 peroxisome proliferator-activated receptor alpha, J Biol Chem, vol.2989, p.2991, 1998.

P. J. Davies and H. Taegtmeyer, Uncoupling protein 3 transcription is regulated by 2992 peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. 2993 FASEB journal : official publication of the Federation of American Societies 2994 for, Proceedings of the National Academy of Sciences of the United States of 3045 America, vol.15, pp.4653-4657, 1992.

B. Vessby, H. Lithell, and H. Ledermann, Elevated lipoprotein lipase activity in 3047 skeletal muscle tissue during treatment of hypertriglyceridaemic patients with 3048 bezafibrate, Atherosclerosis, vol.44, pp.113-118, 1982.

G. L. Vega, N. B. Cater, D. R. Hadizadeh, S. Meguro, and S. M. Grundy, Free fatty 3050 acid metabolism during fenofibrate treatment of the metabolic syndrome

, Clinical pharmacology and therapeutics, vol.74, pp.236-244, 2003.

A. P. Goldberg, D. M. Applebaum-bowden, E. L. Bierman, W. R. Hazzard, and L. B. Haas, , p.3053

D. J. Sherrard, J. D. Brunzell, J. K. Huttunen, C. Ehnholm, and E. A. Nikkila, Increase in 3054 lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in 3055 patients on hemodialysis, The New England journal of medicine, vol.3056, pp.1073-1076, 1979.

H. Lithell, J. Boberg, K. Hellsing, G. Lundqvist, and B. Vessby, Increase of the 3058 lipoprotein-lipase activity in human skeletal muscle during clofibrate 3059 administration, European journal of clinical investigation, vol.8, pp.67-74, 1978.

K. Anderlova, R. Dolezalova, J. Housova, L. Bosanska, D. Haluzikova et al., Influence of PPAR-alpha agonist fenofibrate on insulin 3062 sensitivity and selected adipose tissue-derived hormones in obese women with 3063 type 2 diabetes, Physiological research, vol.56, pp.579-586, 2007.

H. Wu, L. Wei, Y. Bao, J. Lu, P. Huang et al., Fenofibrate 3065 reduces serum retinol-binding protein-4 by suppressing its expression in 3066 adipose tissue, Am J Physiol Endocrinol Metab, vol.296, pp.628-634, 2009.

R. B. Simsolo, J. M. Ong, and P. A. Kern, Effect of gemfibrozil on adipose tissue and 3068 muscle lipoprotein lipase, Metabolism: clinical and experimental, vol.3069, pp.1486-1491, 1993.

K. G. Taylor, G. Holdsworth, and D. J. Galton, Clofibrate increases lipoprotein-lipase 3071 activity in adipose tissue of hypertriglyceridaemic patients, Lancet, p.3072

. England, , vol.2, pp.1106-1107, 1977.

M. Dumont, P. Mauriege, J. Bergeron, J. P. Despres, and D. Prud'homme, Effect of a 3074 six month gemfibrozil treatment and dietary recommendations on the 3075 metabolic risk profile of visceral obese men, Int J Obes Relat Metab Disord, vol.3076, pp.1136-1143, 2001.

C. Fernandez-miranda, M. Perez-carreras, F. Colina, G. Lopez-alonso, C. Vargas-3078 et al., A pilot trial of fenofibrate for the treatment of non-3079 alcoholic fatty liver disease. Digestive and liver disease : official journal of the 3080 Italian Society of Gastroenterology and the Italian Association for the Study of 3081 the, Liver, vol.40, pp.200-205, 2008.

M. Bajaj, S. Suraamornkul, L. J. Hardies, L. Glass, N. Musi et al., 3083 Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and 3084 PPAR-gamma agonists on glucose and lipid metabolism in patients with type 3085 2 diabetes mellitus, Diabetologia, vol.50, pp.1723-1731, 2007.

M. Nakamuta, S. Morizono, Y. Soejima, T. Yoshizumi, S. Aishima et al., , p.3087

K. Yoshimitsu, M. Enjoji, K. Kotoh, A. Taketomi, H. Uchiyama et al., , p.3088

H. Nawata and Y. Maehara, Short-term intensive treatment for donors with hepatic 3089 steatosis in living-donor liver transplantation, Transplantation, vol.80, p.612, 2005.

P. R. Colville-nash, S. S. Qureshi, D. Willis, and D. A. Willoughby, Inhibition of 3092 inducible nitric oxide synthase by peroxisome proliferator-activated receptor

L. Michalik and W. Wahli, Peroxisome proliferator-activated receptors (PPARs) in 3437 skin health, repair and disease, Biochim Biophys Acta, vol.1771, pp.991-998, 2007.

L. Michalik, B. Desvergne, N. S. Tan, S. Basu-modak, P. Escher et al., , p.3439

J. M. Peters, G. Kaya, F. J. Gonzalez, J. Zakany, D. Metzger et al., Impaired skin wound healing in peroxisome proliferator-3441 activated receptor (PPAR)alpha and PPARbeta mutant mice, The Journal of 3442 cell biology, vol.154, pp.799-814, 2001.